22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › DENALI THERAPEUTICS INC. › 2024-2025

DENALI THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and DENALI THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 251Asset managers, any item
  • 1,630Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 5 items on DENALI THERAPEUTICS INC.’s Form 8-K, filed June 3, 2025: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (46.4% against).

Notable dissent: 2 directors (18.9%, 12.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore DENALI THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by DENALI THERAPEUTICS INC.

These tallies are DENALI THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

DENALI THERAPEUTICS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Julian Baker 98,032,346---- 22,859,13110,176,385 81%Elected—
Elect Director: Peter Klein 106,248,604---- 14,642,87310,176,385 88%Elected—
Elect Director: Steve Krognes 64,815,389---- 56,076,08810,176,385 53.6%Elected—
2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 130,831,208194,18242,472 ---- 99.9%Approved—
3. Advisory Vote to Approve Executive Compensation 109,412,77410,796,945681,758 --10,176,385 91%Approved—

Source: DENALI THERAPEUTICS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.

How asset managers voted at the DENALI THERAPEUTICS INC. 2024-2025 meeting

251 asset managers disclosed a vote on at least one DENALI THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Julian Baker

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 98,032,346WITHHELD: 22,859,131
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Julian Baker

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julian Baker”): 98,032,346 for, 22,859,131 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 44,219,761 for, 13,201,551 withheld, 96,204 abstained.

FORWITHHOLD
FOR: 44,219,761ABSTAIN: 96,204WITHHOLD: 13,201,551
Largest asset managers voting on “ELECTION OF DIRECTORS: Julian Baker” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard14,510,3500 010,728,901Mixed
Fidelity8,000,8130 00For
BlackRock4,793,3870 00For
T. Rowe Price4,069,1380 00For
Capital Group3,462,0060 00For
State Street1,502,8640 058For
AllianceBernstein00 01,057,610Withhold
NEW ECONOMY FUND1,024,4290 00For
Charles Schwab1,015,5140 00For
Dimensional779,9400 00For
Aberdeen759,8150 00For
Principal506,1000 0209,758Mixed
AB DISCOVERY GROWTH FUND, INC.00 0614,855Withhold
Equitable231,4060 0370,890Mixed
BNY Mellon446,0020 00For
Artisan423,0410 00For
Yiheng Capital Management, L.P.318,2390 00For
TIAA316,5750 00For
QUANTITATIVE MASTER SERIES LLC211,9290 00For
Brighthouse170,3930 010,141Mixed
Lincoln Financial155,8630 00For
American Century136,1500 00For
New York Life91,3440 026,144Mixed
Jackson National111,7970 00For
ALPS ETF Trust111,3750 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Peter Klein

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 106,248,604WITHHELD: 14,642,873
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Peter Klein

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Klein”): 106,248,604 for, 14,642,873 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 52,697,344 for, 4,788,854 withheld, 31,319 abstained.

FOR
FOR: 52,697,344ABSTAIN: 31,319WITHHOLD: 4,788,854
Largest asset managers voting on “ELECTION OF DIRECTORS: Peter Klein” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard25,239,2510 00For
Fidelity8,000,8130 00For
BlackRock4,793,3870 00For
T. Rowe Price4,069,1380 00For
Capital Group3,462,0060 00For
State Street5,1350 01,497,787Withhold
AllianceBernstein00 01,057,610Withhold
NEW ECONOMY FUND1,024,4290 00For
Charles Schwab1,015,5140 00For
Dimensional00 0779,940Withhold
Aberdeen759,8150 00For
Principal506,3740 0209,484Mixed
AB DISCOVERY GROWTH FUND, INC.00 0614,855Withhold
Equitable231,4060 0370,890Mixed
BNY Mellon446,0020 00For
Artisan423,0410 00For
Yiheng Capital Management, L.P.318,2390 00For
TIAA316,5750 00For
QUANTITATIVE MASTER SERIES LLC211,9290 00For
Brighthouse180,5340 00For
Lincoln Financial55,9310 099,932Mixed
American Century136,1500 00For
New York Life117,4880 00For
Jackson National86,2510 25,5460Mixed
ALPS ETF Trust111,3750 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Steve Krognes

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

53.6% Majority: yes · of votes cast

FOR 53.6%WITHHELD
FOR: 64,815,389WITHHELD: 56,076,088
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Steve Krognes

DENALI THERAPEUTICS INC.’s own tally for this item (“Elect Director: Steve Krognes”): 64,815,389 for, 56,076,088 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2028 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 53.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 21,924,797 for, 30,243,117 withheld, 5,349,603 abstained.

FORWITHHOLD
FOR: 21,924,797ABSTAIN: 5,349,603WITHHOLD: 30,243,117
Largest asset managers voting on “ELECTION OF DIRECTORS: Steve Krognes” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard13,755,7010 011,483,549Mixed
Fidelity00 08,000,813Withhold
BlackRock00 4,793,3870Abstain
T. Rowe Price00 04,069,138Withhold
Capital Group3,462,0060 00For
State Street3,4720 01,499,450Withhold
AllianceBernstein1,057,6100 00For
NEW ECONOMY FUND1,024,4290 00For
Charles Schwab00 01,015,514Withhold
Dimensional00 0779,940Withhold
Aberdeen00 0759,815Withhold
Principal209,7580 0506,100Mixed
AB DISCOVERY GROWTH FUND, INC.614,8550 00For
Equitable370,8900 0231,406Mixed
BNY Mellon446,0020 00For
Artisan423,0410 00For
Yiheng Capital Management, L.P.318,2390 00For
TIAA00 0316,575Withhold
QUANTITATIVE MASTER SERIES LLC00 211,9290Abstain
Brighthouse00 0180,534Withhold
Lincoln Financial00 0155,863Withhold
American Century00 0136,150Withhold
New York Life26,1440 091,344Mixed
Jackson National2,1070 109,6900Abstain
ALPS ETF Trust00 0111,375Withhold

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Advisory Vote to Approve Executive Compensation

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%
FOR: 109,412,774AGAINST: 10,796,945

Prior year: 92.2% for (May 31, 2024 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 251 asset managers

Description as filed by funds: Advisory Vote to Ratify Named Executive Officers' Compensation

DENALI THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote to Approve Executive Compensation”): 109,412,774 for, 10,796,945 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Advisory Vote to Approve Executive Compensation The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 70 asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard25,239,2510 00For
Fidelity8,000,8130 00For
BlackRock4,793,3870 00For
T. Rowe Price4,069,1380 00For
Capital Group03,462,006 00Against
State Street1,502,9220 00For
AllianceBernstein1,057,6100 00For
NEW ECONOMY FUND01,024,429 00Against
Charles Schwab1,015,5140 00For
Dimensional779,9400 00For
Aberdeen759,8150 00For
Principal715,8580 00For
AB DISCOVERY GROWTH FUND, INC.614,8550 00For
Equitable602,2960 00For
BNY Mellon446,0020 00For
Artisan423,0410 00For
TIAA316,5750 00For
QUANTITATIVE MASTER SERIES LLC211,9290 00For
Brighthouse180,5340 00For
Lincoln Financial155,8630 00For
American Century136,1500 00For
New York Life117,4880 00For
Jackson National111,7970 00For
ALPS ETF Trust111,3750 00For
Segall Bryant & Hamill Trust93,5360 00For

Fund voting reports, all 70 managers: 52,637,371 for, 4,523,612 against, 38,295 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 203 asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Wellington12,223,2240 00For
BAILLIE GIFFORD & CO LTD8,466,9030 00For
Fidelity7,479,1610 00For
Temasek Holdings (Private) Ltd5,355,8320 00For
T. Rowe Price5,306,7790 00For
Capital Research Global Investors04,542,711 00Against
State Street3,941,9760 00For
BlackRock3,861,4120 00For
UBS03,798,232 00Against
BAKER BROS. ADVISORS LP3,731,6950 00For
BAILLIE GIFFORD OVERSEAS LTD3,047,9370 00For
GEODE CAPITAL MANAGEMENT, LLC2,988,6360 00For
AllianceBernstein2,899,3360 00For
Camber Capital Management LP1,250,0000 00For
MARSHALL WACE, LLP1,114,6930 00For
Charles Schwab1,033,6700 00For
Fisher Asset Management, LLC992,5360 00For
Casdin Capital, LLC890,0000 00For
Candriam S.C.A.0858,162 00Against
Aberdeen759,8150 00For
Northern Trust753,1680 00For
Citadel730,5970 00For
Siren, L.L.C.728,9990 00For
PRINCIPAL GLOBAL INVESTORS721,3040 00For
Cercano Management LLC625,0000 00For

Institutional-manager reports, all 203 managers: 76,415,858 for, 10,025,008 against, 1,347 abstained, 4,363 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 130,831,208AGAINST: 194,182

Prior year: 99.8% for (May 31, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025

DENALI THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, ”): 130,831,208 for, 194,182 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 57,441,987 for, 37,235 against, 38,295 abstained.

FOR
FOR: 57,441,987AGAINST: 37,235ABSTAIN: 38,295
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at DENALI THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard25,239,2510 00For
Fidelity8,000,8130 00For
BlackRock4,793,3870 00For
T. Rowe Price4,069,1380 00For
Capital Group3,462,0060 00For
State Street1,502,86458 00For
AllianceBernstein1,057,6100 00For
NEW ECONOMY FUND1,024,4290 00For
Charles Schwab1,015,5140 00For
Dimensional779,9400 00For
Aberdeen759,8150 00For
Principal715,8580 00For
AB DISCOVERY GROWTH FUND, INC.614,8550 00For
Equitable602,2960 00For
BNY Mellon446,0020 00For
Artisan423,0410 00For
Yiheng Capital Management, L.P.318,2390 00For
TIAA316,5750 00For
QUANTITATIVE MASTER SERIES LLC211,9290 00For
Brighthouse180,5340 00For
Lincoln Financial155,8630 00For
American Century136,1500 00For
New York Life117,4880 00For
Jackson National111,7970 00For
ALPS ETF Trust111,3750 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Largest DENALI THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 145,251,258 shares outstanding at the time of that meeting.

Fund voting reports: top DENALI THERAPEUTICS INC. shareholders by shares voted on “Advisory Vote to Ratify Named Executive Officers' Compensation”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 17.38%
2Fidelity 5.51%
3BlackRock 3.30%
4T. Rowe Price 2.80%
5Capital Group 2.38%
6State Street 1.03%
7AllianceBernstein 0.73%
8NEW ECONOMY FUND 0.71%
9Charles Schwab 0.70%
10Dimensional 0.54%
Institutional-manager reports: top DENALI THERAPEUTICS INC. shareholders by shares voted on “Advisory Vote to Ratify Named Executive Officers' Compensation”, 2024-2025
#Asset manager % of shares outstanding
1Wellington 8.42%
2BAILLIE GIFFORD & CO LTD 5.83%
3Fidelity 5.15%
4Temasek Holdings (Private) Ltd 3.69%
5T. Rowe Price 3.65%
6Capital Research Global Investors 3.13%
7State Street 2.71%
8BlackRock 2.66%
9UBS 2.61%
10BAKER BROS. ADVISORS LP 2.57%

Reported DENALI THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

DENALI THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock13,834,956 9.52%Form 13F, quarter ended March 31, 2025
BAILLIE GIFFORD & CO12,313,931 8.48%Schedule 13G, filed February 12, 2025
Vanguard Group11,799,757 8.12%Form 13F, quarter ended March 31, 2025
Wellington Management11,409,598 7.86%Form 13F, quarter ended March 31, 2025
Wellington10,727,450 7.39%Proxy statement (DEF 14A), proxy filed April 17, 2025
FMR LLC10,141,901 6.98%Proxy statement (DEF 14A), proxy filed April 17, 2025
Julian C. Baker7,431,485 5.12%Proxy statement (DEF 14A), proxy filed April 17, 2025
FMR (Fidelity)7,413,354 5.10%Form 13F, quarter ended March 31, 2025
Ryan J. Watts, Ph.D.4,545,835 3.13%Proxy statement (DEF 14A), proxy filed April 17, 2025
State Street4,460,757 3.07%Form 13F, quarter ended March 31, 2025

Percentages above are of 145,251,258 shares outstanding, as reported by DENALI THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At DENALI THERAPEUTICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 251 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,630 separate fund positions. On the most widely held item on that ballot — Advisory Vote to Ratify Named Executive Officers' Compensation — DENALI THERAPEUTICS INC.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: DENALI THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from DENALI THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

DENALI THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “DENALI THERAPEUTICS (DNLI) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/denali-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.